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Abstract
Background: Mesiotemporal cavernous malformation can occur in 10–20% of 
patients with cerebral cavernomas and are frequently associated with refractory.
Methods: A retrospective investigation was performed in the epilepsy clinic of a 
Brazilian tertiary referral epilepsy center, from January 2000 to March 2012.
Results: A total of 21 patients were included in the study. Thirteen patients (62%) 
evolved to Engel I; 5 (24%) to Engel II, 2 (10%) to Engel III, and 1 (5%) to Engel 
IV. We observed that 10 (48%) patients with 12 years or less of epilepsy duration 
evolved to Engel I and 1 (5%) to Engel II; whereas from a total of 10 patients with 
epilepsy duration of more than 12 years, 3 (30%) evolved to Engel I and 7 (70%) 
to Engel II, III, or IV (P < 0.001 [bilateral]; P1 ≠ P2).
Conclusion: Postsurgical seizure outcome for temporal lobe epilepsy associated 
with mesiotemporal cavernomas is very satisfactory.
Key Words: Cavernous malformations, mesiotemporal cavernous malformation, 
temporal lobe epilepsy
INTRODUCTION
Cerebral cavernous malformations are known to 
be highly epileptogenic lesions, but the underlying 
epileptogenic mechanisms are not fully understood. 
Asymptomatic microhemorrhages into the surrounding 
brain, with subsequent perifocal hemosiderosis and 
gliosis, are considered the major cause of seizure 
activity.[6] Mesiotemporal cavernomas (MTC) can occur 
in 10–20% of patients with cerebral cavernomas[13,20] and 
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are frequently associated with refractory.[21,22] Surgical 
removal of safely achievable symptomatic lesions has 
been frequently consistent with good long‑term seizure 
outcomes.[8,9,21,22] The aim of the present study is to 
analyze retrospective data on consecutive patients 
with temporal lobe epilepsy associated with MTC 
(TLE‑MTC), surgically treated in a Brazilian tertiary 
epilepsy referral center, in order to assess the effect of 
microsurgical resection on seizure activity and general 
outcome.
METHODS
Study delineation
A retrospective observational investigation was conducted 
with data collection from all inpatients and outpatients 
treated in the epilepsy clinic of Faculdade de Medicina de 
Sao Jose do Rio Preto, a Brazilian tertiary referral epilepsy 
center, diagnosed with TLE‑MTC from January 2000 to 
March 2012. Clinical data were obtained retrospectively 
from the patient records and files. For all patients with 
the diagnosis of MTC on magnetic resonance images 
(MRIs), the following data were collected: Gender, 
age at the surgery, handedness, type and number of 
antiepileptic drugs (AEDs) used, and results of formal 
neuropsychological evaluations. In addition, noninvasive 
video‑electroencephalography (EEG) data and side of 
surgery were registered.
Presurgical evaluation
Patients were submitted to video‑EEG monitoring 
using the Neuro Workbench software (Nihon Kohden 
Corporation) and Nihon Kohden hardware (Nihon 
Kohden Corporation) to record and later evaluated all 
the epileptic events. Every patient was analyzed by an 
experienced epileptologist as an integral part of inpatient 
assessment.
All patients were submitted to a neuropsychological 
assessment pre‑ and post‑surgically (at 12 months). 
Verbal memory was assessed by a list of learning design, 
and figural memory by a design learning test using 
independent items. Memory deficits were defined as 
performance one standard deviation (SD) below of the 
normal performance of age‑matched controls.
Brain MRI was obtained accordingly with specific 
epilepsy protocol using a 1.5 tesla scanner, Philips, at 
the Department of Neuroradiology in our institution. All 
MRIs were analyzed by an experienced neuroradiologist 
that confirmed the visual radiological diagnosis of mesial 
temporal lobe (parahippocampal gyrus, hippocampus, 
amigdalum, and uncus) cavernomas. Displaying the 
sagittal three‑dimensional T1‑weighted gradient‑echo 
sequences, the next sequences were an axial and coronal 
fluid‑attenuated inversion recovery fast spin‑echo (section 
thickness, 3 mm), axial and coronal T2‑weighted fast 
spin‑echo (section thickness, 2 mm) and T1‑weighted 
inversion recovery sequences (section thickness, 5 mm) 
[Figure 1].
Biopsy specimens were obtained from all patients with 
chronic drug‑resistant and radiological evidence of MTC, 
who underwent surgical treatment. Surgical removal 
of the hippocampus was clinically indicated in every 
case, and all the patients were submitted to complete 
lobectomy. The standardized neuropathological analysis 
was performed in all the patients under this study. 
Surgical specimens submitted for neuropathological 
evaluation were microscopically analyzed by using 
hematoxylin and eosin staining. The pathologist reported 
their findings without the clinical or imaging data.
Outcome assessments and follow‑up
Follow‑up investigations were carried out in operated 
patients. At the 12 months follow‑up, all the patients 
received a neurological examination including observation 
of behavior disorders, exploration of seizure outcome, and 
a cerebral 1.5 tesla MRI. Seizure outcome was classified 
as completely seizure‑free since surgery, that is, Engel I, 
or not seizure‑free (Engel II–IV).
Ethical statement
The Ethical Committee of our institution analyzed 
the project of the present study and approved the 
performance of our investigations. The study complies 
with the Declaration of Helsinki. Informed consent was 
taken from all patients and/or genitors.
Statistical analysis
Data collected from all the patients were organized in 
tables. Averages are expressed as the mean ± SD for 
parametric data and as median values for nonparametric 
data. Statistical analysis was performed utilizing the 
Fisher’s exact test. A P < 0.01 was considered statistically 
significant.
Figure 1: Comparison of surgical outcome between the patients 
with ≤ 12 years or > 12 years of epilepsy duration (**P < 0.01, 
Fisher’s exact test)
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RESULTS
Presurg ical  demog raphic  and c l inical 
characteristics
At the moment of the study, 533 patients underwent 
multidisciplinary investigation for epilepsy, and 21 (3.9%) 
patients fulfilled the inclusion criteria of radiological 
and pathological diagnosis of MTC. Table 1 summarizes 
the demographic and clinical data of all patients. The 
presurgical mean age was of 34.38 ± 8.82 years, with 13 
male (61.9%) and 8 female (38.1%). The mean epilepsy 
duration at surgery was of 11.95 ± 4.25 years. Thirteen 
patients (61.9%) had complex partial seizures (CPSs) and 
8 (38.1%) had generalized tonic‑clonic seizures. Nineteen 
(90.5%) patients were right‑handed and 2 (9.5%) 
left‑handed. Nine (42.8%) patients presented a previous 
history of febrile seizure during infancy. Six patients 
(28.6%) were taking a single AED, and 15 (71.4%) were 
taking two or more AEDs. Neuropsychological assessment 
revealed that 5 (23.8%) presented cognitive impairment 
before surgery. In addition, 19 patients (90.5%) presented 
unilateral epileptic discharge on ictal EEG and two 
bilateral (9.5%); 16 subjects (76.2%) had unilateral and 
5 (23.8%) had bilateral epileptic discharges on interictal 
EEG, respectively. Two patients (9.5%) presented with 
multiple (2 or more) lesions and 19 (90.5%) with only one 
lesion on the temporal lobe. The location of the lesion 
was found as follow: 16 (76.2%) on the lateral temporal 
neocortex and 5 (23.8%) affecting mesiotemporal 
structures, that is, two in the head of the hippocampus 
and three in the parahippocampal gyrus. Radiological 
investigation also showed some degree of sclerosis of 
the lateral temporal lobe neocortex and/or the mesial 
structures in 19 (90.5%).
Seizure control and follow‑up
All the patients were followed during a minimum period 
of 1 year and a maximum of 7 years. The mean follow‑up 
duration was of 3.14 ± 1.68 years. Three patients (14%) 
were followed during 1 year; 6 (29%) during 2 years; 
5 (24%) during 3 years; 2 (10%) during 4 years; 2 (10%) 
during 5 years; 1 (5%) during 6 years; and 1 (5%) during 
7 years. Seven patients (33%) stopped their AED; 6 (29%) 
reduced, and 8 (38%) maintained the AED use.
Seizure outcome following surgery revealed that 
13 patients (62%) became Engel I, 5 (24%) to Engel II, 
2 (10%) Engel III, and 1 (5%) Engel IV. We observed 
that 10 (48%) patients with 12 years or less of epilepsy 
duration evolved to Engel I and 1 (5%) to Engel II, 
whereas from a total of 10 patients with epilepsy duration 
of more than 12 years, 3 (30%) evolved to Engel I and 
7 (70%) to Engel II, III, or IV (P < 0.001 [bilateral]; 
P1 ≠ P2) [Figure 1].
Postoperative neuropsychological assessment showed 
deterioration in 4 patients with the previous cognitive 
deficits. One patient recovered to its baseline. No 
Table 1: Clinical data of patients with mesiotemporal cavernomas
Subject 
number
Gender Age Epilepsy 
duration
Seizure 
semiology
AED Cognitive 
deficit
Affected 
hemisphere
Surgical 
technique
Seizure 
outcome
Follow‑up 
(years)
1 Male 21 10 CPS Stopped No Right SAH Ia 2
2 Female 29 11 GTCS Stopped No Right ATL Ia 3
3 Male 33 16 CPS Maintained Yes Left ATL Ic 2
4 Female 28 11 CPS Stopped No Right ATL Ia 3
5 Male 46 17 CPS Maintained Yes Left ATL III 5
6 Male 51 19 GTCS Maintained Yes Left ATL IV 7
7 Female 34 14 CPS Reduced No Right ATL II 2
8 Male 27 12 CPS Reduced No Left ATL Ia 4
9 Female 39 16 GTCS Maintained Yes Left ATL II 1
10 Male 37 14 CPS Reduced No Right SAH Ia 6
11 Male 42 13 GTCS Maintained No Right ATL Ic 5
12 Male 24 7 GTCS Stopped No Left ATL Ia 1
13 Female 36 9 CPS Reduced No Right ATL Ic 3
14 Female 22 4 CPS Stopped No Left SAH Ia 2
15 Male 25 6 GTCS Stopped No Right ATL Ia 3
16 Female 37 12 CPS Reduced No Right ATL Ib 4
17 Male 41 14 CPS Maintained No Right ATL II 2
18 Male 46 18 CPS Maintained Yes Left ATL III 5
19 Female 38 13 GTCS Reduced No Right ATL II 1
20 Male 23 4 CPS Stopped No Right ATL Ia 2
21 Male 43 11 GTCS Maintained No Right ATL II 3
CPS: Complex partial seizure, GTCS: Generalized tonic-clonic seizure,  AED: Antiepileptic drug,  ATL: Anterior temporal lobectomy, SAH: Selective amygdalo-hippocampectomy
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patients with normal cognition preoperatively evolved 
memory deficits. No patients reported visual field defect 
after the surgery.
Complications
No operative death (30 days after surgery) was recorded. 
In the present investigation, 2 (9%) of patients evolved 
with infection of the surgical wound and were treated 
exclusively with oral antibiotics. No additional clinical 
complications where noted.
DISCUSSION
Cavernous brain malformations are vascular lesions with 
an estimated prevalence between 0.4% and 0.9%,[12] 
appearing mainly as singular supratentorial lesions[16] 
frequently associated with refractory seizures.[21,22] In 
addition, 35–80% of all patients with supratentorial 
cavernomas are affected by 1st time seizures, of which up 
to 40% are resistant to AED treatment.[2,10,11,14,17]
In the present study, we presented our surgical series 
of 21 patients with refractory TLE‑MTC. We found an 
average incidence of 1.61 case/year, affecting mainly man 
with age ranging from 30 to 40 years old. It was also 
noted that CPSs was the most common semiological 
feature, present in 62% of patients. Kivelev et al.,[13] in 
2011, and Sommer et al.,[19] in 2013, although showing 
different results regarding gender prevalence, presented 
similar results median age. Elsharkawy et al.[10] and 
Cohen‑Gadol et al.[9] showed that other degenerative 
lesions, such as mesial temporal sclerosis, presented a 
better surgical and seizure outcome in comparison with 
tumors and gliosis. Rydenhag et al.[18] reported the surgical 
treatment of patients with refractory TLE‑MTC, with 
a good seizure control. In the present investigation, 13 
patients (62%) evolved to Engel I and 5 (24%) to Engel 
II, which is consistent with the previous studies.[3,5,18] We 
decide to perform anterior temporal lobectomy associated 
with amigdalo‑hippocampectomy and not only a tailored 
resection of the lesion for some reasons:[1] Some authors 
report that hemosiderin may also be epileptogenic[11,12] 
and, in our cases, sometimes it was difficult to 
differentiate precisely the tissue and how far should we go 
to include all the epileptogenic zone;[2] most patients also 
had some degree of temporal lobe and mesial structures 
sclerosis, and[3] the preoperatory electrophysiological 
features also suggested an epileptogenic zone usually 
wider the cavernous malformation size.
The present study also observed that patients suffering 
from epilepsy for a longer period might present a worse 
seizure outcome. In our analysis, 10 (48%) patients with 
12 years or less of epilepsy duration evolved to Engel I 
and 1 (5%) to Engel II; whereas from the 8 patients with 
epilepsy duration of more than 12 years, 1 (5%) evolved 
to Engel I and 7 (33%) to Engel II, III, or IV (P = 0.0075 
[bilateral]; P1 ≠ P2) [Figure 1]. Our results are in 
agreement with investigators who reported that seizure 
outcome can be improved if epilepsy surgery is considered 
earlier in patients with epileptogenic lesions.[1,4,7,14,15,18]
There are several methodological aspects in the present 
findings, which should be interpreted in the context 
of a number of limitations. First, this study is a 
nonrandomized, retrospective investigation performed in 
a highly selected population of a tertiary epilepsy center. 
Second, these findings cannot be generalized for all types 
of TLE since the patients with dual pathology, or single 
disease other than MTC were excluded. On the other 
hand, the present study described the surgical outcomes 
of a relatively large number of patients that underwent 
surgery due to this uncommon pathology for a relatively 
extended follow‑up duration.
CONCLUSION
The present study highlights that seizure outcome after 
respective epilepsy surgery for epileptogenic lesions, 
especially MTC, in adults is very satisfactory. However, 
surgical treatment should be considered early in the 
course of the disease to improve seizure control and to 
reduce suffering.
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